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ABSTRACT Sometrialsadministeredantituberculosisagentsfor5of7days(5/7-dayregimen)tooptimizeadherence.Sincemoxi-
ﬂoxacinhasalongerhalf-lifethanrifampin,rifampinconcentrationsare <1%ofthemaximumconcentrationinserum(Cmax)
onday6andnondetectableonday7,whileconcentrationsofmoxiﬂoxacinremainandareabletoinduceerror-pronereplica-
tion. We determined if functional moxiﬂoxacin monotherapy for 24 h/week caused resistance. In in vitro pharmacodynamic
experiments, Mycobacterium tuberculosis was treated with mean area under the concentration-time curve (AUC) exposures for
moxiﬂoxacinandrifampinof400and600mg/kg/dayandexposuresequalto1standarddeviation(SD)aboveandbelowthe
meanvalues.Thedrugswereadministeredonschedulesof7/7daysand5/7days.Overthe28-dayexperiments,bacteriawere
platedontoantibiotic-freeagartodeterminetheeffectsofexposureandscheduleonthetotalpopulation.MICswerecheckedfor
emergenceofresistance.Atdays7and14,therewasa0.56-to1.22-log10-CFU/mlgreatercellkillwiththe7/7-dayregimenversus
the5/7-dayregimen(lowexposure).Thisdifferencewasnotseenforthelargerexposuresatday21.Atday23,thelow-exposure
5/7-dayarmhadbreakthroughresistance,withthetotalcountincreasingto >2log10CFU/mlabovethelow-exposure7/7-day
arm.Pharmacokineticmismatchingofdrugsinthetherapyoftuberculosismayresultinemergenceofresistancewhenadrug
holidayisimposedduringwhichthereisfunctionalmonotherapyandwheretheremainingagentinduceserror-pronereplica-
tion.Thisisparticularlytruefortheportionofthepopulationwheretheclearanceishigher(1SDabovethemean).
IMPORTANCE Directly observed therapy is a cornerstone of treatment of Mycobacterium tuberculosis. Patients are often given a
drugholidaytofacilitatethedirectobservationoftherapy.Withrifampinandmoxiﬂoxacin,thereisadiscordancebetweenthe
half-livesoftheseagents(1.9versus6.5hwhenemployedincombination).Inaddition,moxiﬂoxacininduceserror-pronerepli-
cation in Mycobacterium tuberculosis. In this experiment, we demonstrate that the drug holiday (5 of 7 days of therapy [5/7-day
regimen])allowstheemergenceofresistancetomoxiﬂoxacin,whichwasnotseenwith7/7-daytherapy.Ifdrugholidaysare
used,itisimperativetobettermatchpharmacokineticstominimizetheriskofemergenceofresistance.
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A
number of clinical and preclinical studies have administered
therapy for Mycobacterium tuberculosis on a schedule of
5 days out of 7 days (5/7-day regimen), with the idea that this
would improve regimen adherence. Most recently, these trials
haveincludedmoxiﬂoxacinandrifampinaspartofthetherapy
(1, 2). Moxiﬂoxacin and rifampin have somewhat discordant
serum half-lives, and they have been demonstrated by Weiner
etal.(3)tointeract,causingmoxiﬂoxacinclearancetoincrease
(and the moxiﬂoxacin area under the concentration-time
curve [AUC] to decrease) by 27% when administered in the
presence of rifampin.
The discordance in serum half-lives of moxiﬂoxacin and
rifampin may have important implications. Over the 48 h in
which both drugs are not administered, the concentration of
rifampin will be less than 1% of the peak concentration at the
end of the ﬁrst day and undetectable on the second day, while
moxiﬂoxacin still retains considerable concentrations during
this period because of its longer half-life. Furthermore, as a
ﬂuoroquinolone, moxiﬂoxacin induces error-prone replica-
tion in M. tuberculosis (4). Consequently, it is reasonable to
hypothesize that the discordance in half-lives may lead to
emergence of resistance to one or both drugs. We decided to
test this hypothesis with our hollow ﬁber infection model
(HFIM) (Fig. 1). We compared the impacts of drug exposures
on 7/7-day and a 5/7-day dosing schedules on breakthrough
regrowth over 28 days and assessed whether regrowth was due
toemergenceofresistancetoeithermoxiﬂoxacin(expected)or
rifampin. The ability to suppress resistance with combination
chemotherapy is a key factor in the ultimate outcome of ther-
apy for M. tuberculosis.
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Organism rifampin and moxiﬂoxacin MICs and mutation fre-
quencies. For M. tuberculosis strain H37Ra, the MIC for rifampin
was 0.06 mg/liter and the mutation frequency to 2.0 mg/liter of
rifampin was 1/6.921 log10 CFU. For moxiﬂoxacin, the MIC was
0.25 mg/liter and the mutation frequency to resistance to 1.0 mg/
liter was 1/6.524 log10 CFU.
M. tuberculosis cell kill for different drug exposures and
schedules of administration. Examination of the top panel of
Fig.2Ademonstratesthattheadministrationofmoxiﬂoxacinplus
rifampin provided excellent cell kill over time when the drugs
were administered 7/7 days. The relatively small free 24-h AUC
(AUC
24 h) exposure range examined did not result in a reliable
exposure response for the organism kill. At day 28, the cell kill
results for all three regimens (mean AUC for both drugs from the
paper by Weiner [3]  1 standard deviation [SD]) for this group
were essentially identical. This was recapitulated in the second
independent experiment (top panel of Fig. 2B).
Importantly, in the groups treated 5/7 days with moxiﬂoxacin
and rifampin, there was a general trend for the cell kill to be less
thanthatinthegrouptreated7/7days,buttheantimicrobialeffect
was not statistically different until after day 21. At this juncture,
there was clear discordance among the regimens. The highest-
exposure regimens performed nearly identically at both 5/7 days
and7/7days(topandbottompanelsofFig.2Afortheﬁrstexper-
iment and top and bottom panels of Fig. 2B for the second exper-
iment). However, in the lowest-exposure groups of the two ad-
ministration schedules, there was a 2.25- to 2.5-log10-CFU/ml
difference between the 7/7-day treatment group and the 5/7-day
group in both experimental trials (top versus bottom panels of
Fig. 2A and B).
The ultimate difference, which largely explains the cell kill dif-
ferences in the two schedules of administration, comes from the
identiﬁcation of emergence of resisitance
in both performances of the experiment,
solely in the low-exposure group in the
5/7-day administration schedule. The
MIC for moxiﬂoxacin increased from
0.25 mg/liter to 1.0 mg/liter, while the
MIC for rifampin remained wild type.
Attainment of nominal
concentration-time proﬁles. The simu-
lated pharmacokinetic (PK) proﬁles for
the ﬁrst 72 h of the critical contrast arms
(Fig. 3A, arm B—success versus arm E—
failure) are displayed. The achieved drug
concentrations for both agents were well
matched between arms, indicating the
difference in outcome is not attributable
to difference in drug exposure, at least on
a daily basis. For the other arms, the data
indicate that the actual concentrations
achieved were within approximately 10%
of nominal. This was also true of the par-
allel experiment. For the lowest-exposure
groups, the free AUC0-168 h values for
moxiﬂoxacin were 68.9 mg·h/liter for the
7/7-day schedule and 50.86 mg·h/liter for
the 5/7-day group. For rifampin, the free
AUC
0-168 hvalueswere29.47mg·h/literand
22.12 mg·h/liter, respectively. On a per-day basis, the 5/7-day
schedule group was marginally higher than the 7/7-day schedule
group for both drugs (i.e., weekly exposure AUC0-168 h values di-
vided by 7 and 5, respectively).
DISCUSSION
In the therapy of tuberculosis, maintenance of drug susceptibility
is critical. Emergence of resistance has two main roots. The ﬁrst is
inadequate drug therapy. Getting the dose wrong may have con-
sequences for rapid emergence of resistance, even in the combi-
nationchemotherapysetting.Thesecondisregimenadherence.It
may be argued that adherence is at least as important as drug
regimen and perhaps may be a more important cause of emer-
gence of resistance.
Inordertominimizeregimennonadherence,directlyobserved
therapy was instituted for use with treatment that includes the
standard ﬁrst-line antituberculosis drugs (rifampin, isoniazid,
and pyrazinamide). Because of the practical difﬁculty of seeing
each patient on 7/7 days, regimens have been designed with short
drug holidays which, given the relatively long turnover half-time
of M. tuberculosis (circa 20 h), should result in minimal regrowth
over the standard gap of 2 days.
We felt that the combination of moxiﬂoxacin plus rifampin
might be a special case with regard to emergence of resistance,
becausetheserumhalf-livesofthedrugsthatareactiveagainstM.
tuberculosisinlog-phasegrowtharemismatched.Weineretal.(3)
found that there was drug interaction in volunteers, such that at
2weeks,thehalf-lifeofmoxiﬂoxacinof10.42.0hwhenadmin-
istered alone decreased to 6.5  0.9 h when moxiﬂoxacin was
administered in combination with rifampin. Rifampin, studied
only in combination, had a half-life of 1.9  0.3 h. For a no-drug
period of 48 h, rifampin will be essentially gone within the ﬁrst
24h(12terminalhalf-lives),whiletherewillstillbesomemoxi-
FIG 1 Hollow ﬁber infection model system.
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demonstrated that low concentrations of a ﬂuoroquinolone
caused rapid upregulation of some of the components of the SOS
responseinM.tuberculosis.Concentrationsofciproﬂoxacinof1/4
and1/2theMICresultedinupregulationofexpressionoflexAand
recA within4ha n ddnaE2 within 24 h. Given the kinetics of
moxiﬂoxacin in the serum of patients, we hypothesized that the
induction of error-prone replication would, after a number of
rounds of replication, result in emergence of resistance.
We employed exposures at the mean of the free AUC24 h for
moxiﬂoxacin and rifampin (3) as well as the free AUC24 hs that
were 1 SD above and below the mean exposure. Our previous
publication examining this combination (5) demonstrated that,
whenadministeredonadailybasis,evensmallexposurestorifam-
pin in combination with moxiﬂoxacin still suppressed resistance.
We performed the experiment completely independently with
two different teams at the same time. Examination of the top
panels of Fig. 2A and B shows that, when administered 7/7 days,
there was little evidence of an exposure response, and at day 28,
there was no emergence of resistance.
In contrast, using the 5/7-day schedule, there was a divergence
in the colony counts that became manifest after day 23 in both
experiments, with a 2.25- to 2.5-log10-CFU/ml increase in colony
countswhencontrastingthelowestexposurearmsofthe7/7-and
5/7-dayexperiments(armBversusarmEinFig.2AandB).More
importantly,thelow-exposurearm(armE)allowedemergenceof
resistance for moxiﬂoxacin (4-fold increase in baseline MIC) in
both experiments. It is important to note that in a normal distri-
bution,15.8%ofthetotalpopulationwillhaveanAUCvalueator
below the value of the mean  1 SD. This places a considerable
fraction of the population at risk in this circumstance.
In conclusion, the results were able to be replicated, and in
both instances, resistance emerged in the lowest-exposure arms,
but not in the two higher-exposure arms when the drugs were
administered 5/7 days. Administration of moxiﬂoxacin and ri-
fampin on a 7/7-day schedule suppressed resistance, even at the
lowest exposure. This is concordant with our earlier publication
(6). The emergence of resistance explained the increase in colony
counts in the low-exposure arms in the 5/7-day administration
schedule relative to the 7/7-day schedule (increase of 2.25 to 2.5
log10CFU/mlinarmBversusarmE).Theoutcomeswerenotdue
to differences in achieved drug concentrations. Resistance oc-
curred only to moxiﬂoxacin.
When holiday schedules are designed to enhance regimen ad-
herence, attention should be paid to whether or not error-prone
replication is induced by one of the drugs, and there should be no
discordanceinthePKproﬁlessothatbothdrugsareconcurrently
available to help suppress resistance. In the case of moxiﬂoxacin
FIG 2 (A) First trial of moxiﬂoxacin-plus-rifampin 7/7-day versus 5/7-day regimens. The AUC exposures in the symbol keys are the free AUC24 hs that were
infused into that particular hollow ﬁber system experimental arm on the days that the drugs were administered. (B) Second trial of moxiﬂoxacin-plus-rifampin
7/7-day versus 5/7-day regimens. The AUC exposures in the ﬁgure legends are the free AUC24 hs that were infused into that particular hollow ﬁber system
experimentalarmonthedaysthatthedrugswereadministered.Thereisre-growthbetweenday23andday28,speciﬁcallyinthelowestexposuregroup(armE)
intheexperimentalarmwherethedrugswereadministered5/7days.Therewasa2.25Log10(CFU/ml)differencebetweenarmsBandE,attributabletodifference
in administration schedule and weekly drug exposures. In arm E colonies recovered had a wild-type MIC for rifampin (0.03 mg/L), but increased 4-fold for
moxiﬂoxacin (0.25 to 1.0 mg/L).
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a 5/7-day administration schedule is to be contemplated since
rifapentine has a serum half-life in humans of 13 h (5) compared
with a 1.9-h serum half-life for rifampin.
MATERIALS AND METHODS
Bacterial isolate. M. tuberculosis H37Ra (ATCC 25177; American Type
CultureCollection)wasusedinourstudies.Bacterialcultureswerestored
at 80°C in Middlebrook 7H9 broth with 10% albumin-dextrose-
catalase (ADC) and 0.025% Tween 80 (Becton Dickinson), and aliquots
were thawed for study. The cultures were incubated in Middlebrook 7H9
broth with 10% ADC at 37°C with 5% CO2 for 4 days to achieve
exponential-phase growth.
Antimicrobial agents. Rifampin was obtained from Sigma-Aldrich,
Inc.(St.Louis,MO).Stocksolutionswerepreparedindimethylsulfoxide
(DMSO),andaliquotswerestoredat–80°C.Moxiﬂoxacinwaspurchased
fromCuraScriptSD(Orlando,FL).Stocksolutionsofthisantibioticwere
prepared in sterile water, and aliquots were stored at –80°C. For each
study, a sample of each drug was thawed, diluted to the desired concen-
tration in sterile water or Middlebrook 7H9 broth with ADC, and used
immediately. The concentration of DMSO that was infused into the hol-
lowﬁbersystemswithdrugadministrationdidnotaffectthegrowthofthe
bacterium.
MICdetermination.TheMICsformoxiﬂoxacinandrifampinforthe
M. tuberculosis isolate were determined by plating 10 lo f1
106CFU/mloflog-phase-growthbacteriumontoMiddlebrook7H10plus
10% oleic acid, albumen, dextrose, and catalase (OADC) agar containing
geometric 2-fold dilutions of rifampin or moxiﬂoxacin. Plates were incu-
bated at 37°C with 5% CO2 in ambient air. The results were read after
21 days of incubation. The MIC was deﬁned as the lowest concentration
that allowed growth of M. tuberculosis of 1% compared with untreated
controls.
Mutation frequency determinations. M. tuberculosis H37Ra was
grown to exponential-phase growth in 7H9 broth plus ADC, as described
above. On the fourth day, the mutation frequency (MF) in the cultures
was determined by plating 5 ml of the bacterium onto plates containing
Middlebrook 7H10 plus OADC containing either 32 MIC of rifampin
or 4 MIC of moxiﬂoxacin. The mutation frequency was determined
after 21 days of incubation at 37°C with 5% CO2. This determination was
performed aerobically.
Hollow ﬁber infection model. The hollow ﬁber infection model
(HFIM) permits us to simulate the concentration-time proﬁle for any
dose of antibiotic (Fig. 1). A computer-controlled syringe pump delivers
theantibioticintoacentralreservoirintherequiredamountatthedesired
schedule of administration. Fresh medium is pumped into the system
while drug-containing medium is isovolumetrically removed from the
system at rates programmed by the investigator to simulate the desired
drug half-life.
In these experiments, 15 ml of M. tuberculosis H37Ra was inoculated
into the peripheral compartments of hollow ﬁber cartridges at a concen-
trationof1106 to5106CFU/ml.UsinghumanPKparametersfrom
Weiner et al. (3), the free-drug serum concentration-time proﬁles for
moxiﬂoxacinandrifampinweresimulated.ThefreemeanvaluesofAUC
ofbothagentswereused,butalsoregimenswithfreeAUCexposuresthat
FIG 3 Moxiﬂoxacin and rifampin concentrations (g/ml) for the successful arm (A; arm B) versus failure arm (B; arm E). Solid curves are the targeted
concentration-time proﬁles to be simulated in the hollow ﬁber systems. The red triangles are the measured concentrations of the respective drugs over the ﬁrst
72 h of each experiment.
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a no-treatment control. The experiment lasted for 28 days. The experi-
ment was conducted in duplicate.
As combination therapy was employed with drugs with signiﬁcantly
different half-lives, the correct and quite different half-lives for rifampin
and moxiﬂoxacin were developed using the approach of Blaser (7).
Bacterialsamples(400l)weretakenfromeachhollowﬁbercartridge
and were washed twice with sterile saline to prevent drug carryover. The
samples were sonicated, vortexed, and then quantitatively plated onto
7H10-OADCagarstoidentifytheeffectofeachdrugexposureandsched-
ule of administration on the total M. tuberculosis populations. After the
plates were incubated at 37°C in 5% CO2 for 21 days, the colonies were
counted. Multiple colonies were picked and retested for both rifampin
and moxiﬂoxacin MIC values to look for emergence of resistance.
To document the concentration-time proﬁles, the central reservoir
was sampled 22 times over 60 h for determination of both moxiﬂoxacin
and rifampin concentrations by liquid chromatography-tandem mass
spectroscopy (LC-MS/MS).
Determination of moxiﬂoxacin and rifampin concentrations.
Middlebrook7H9-ADCmediumPKsimulationsamples(0.050ml)were
added to autosampler vials containing 1.00 ml high-performance liquid
chromatography (HPLC) water and 0.050 ml d3-rifampin internal stan-
dard. They were analyzed by high-pressure liquid chromatography-
tandem mass spectrometry (LC-MS/MS) simultaneously for moxiﬂoxa-
cin and rifampin concentrations. The LC-MS/MS system was comprised
of a Shimadzu Prominence HPLC system and an ABSciex API5000 LC-
MS/MS.
Chromatographic separation was performed using a Thermo Scien-
tiﬁc Hypersil gold C18 column (5 m, 1,500 by 4.6 mm) employing a
gradient using mobile phases of 0.1% formic acid in water and methanol
at a ﬂow rate of 1.00 ml/min.
Moxiﬂoxacin and rifampin concentrations were obtained concur-
rently using LC-MS/MS monitoring the MS/MS transitions m/z 402 ¡
m/z 384 for moxiﬂoxacin, m/z 823 ¡ m/z 791 for rifampin, and m/z 826
¡ m/z 794 for d3-rifampin. The analysis run time was 7.0 min.
The assay was linear over a range of 0.0050 to 5.00 g/ml (r2  0.993)
forbothmoxiﬂoxacinandrifampin.Theinterdaycoefﬁcientsofvariation
(CVs) for the quality control samples, containing both moxiﬂoxacin and
rifampin, analyzed in replicates of four at three concentrations (0.0100,
0.100,and1.00g/ml)oneachanalysisdayrangedfromto4.94to8.82%
formoxiﬂoxacinand5.91to9.66%forrifampin.Accuracies(%recovery)
forthesamequalitycontrolsamplesrangedbetween97.4%and107%for
moxiﬂoxacin and between 98.7 and 103% for rifampin.
Pharmacokinetic parameter identiﬁcation and AUC calculation.
Thepharmacokineticsofmoxiﬂoxacinandrifampinwereestimatedfrom
the concentration-time proﬁles of both drugs using the ADAPT II pack-
age of programs of D’Argenio and Schumitzky (8). As the computer-
controlled pumps were set to produce a single exponential decline, no
model ﬁnding was performed and a 1-compartment model was ﬁt to the
data with maximum likelihood estimation.
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